Organogenesis ORGO
1.41
(0.01)
(0.70%)
as of 25 Sep
- Market cap
- $207.1M
- P/E
- 0.0×
Follow ORGO
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 57.56 | 0.00 | 0.00 |
P/S ratio |
1.15 | 1.16 | 0.59 | 0.68 | |
P/FCF ratio |
0.00 | 0.00 | 17.73 | 15.00 | |
P/Operating CF |
173.90 | 16.65 | 14.34 | (9.88) | |
P/B ratio |
2.10 | 2.19 | 1.24 | 2.11 | |
Price to Tangible BV |
2.47 | 2.50 | 1.43 | 2.68 | |
EV/Sales |
1.03 | 1.03 | 0.45 | 0.62 | |
EV/EBITDA |
26.66 | 8.11 | 6.44 | 0.00 | |
EV/Operating CF |
(12.35) | (56.35) | 7.45 | 8.84 | |
EV/FCF |
(9.28) | (23.75) | 13.41 | 13.56 | |
Quick Ratio |
2.58 | 3.11 | 2.75 | 2.59 | |
Current Ratio |
3.32 | 3.62 | 3.53 | 3.52 | |
Net Debt/EBITDA |
(2.25) | (1.16) | 1.41 | 0.81 | |
Debt/Assets |
0.41% | 2.14% | 2.38% | 2.66% | |
Debt/Equity |
0.01 | 0.04 | 0.05 | 0.07 | |
Asset Turnover |
0.97 | 1.03 | 1.04 | 1.05 | |
Operating CF/Net income |
0.21 | 1.00 | (0.38) | 0.32 | |
Capex/Depreciation |
(0.32) | (0.66) | (0.25) | (0.17) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
8.76% | 4.56% | 40.72% | 41.82% | |
Selling, General and Administrative Expense of Revenue |
52.86% | 44.40% | 175.10% | 123.33% | |
Intangible Assets out of Total Assets |
0.08 | 0.06 | 0.06 | 0.08 | |
Share Based Compensation of Revenue |
2.03% | 1.92% | 9.77% | 6.98% | |
Graham Net Nets |
0.08 | 0.10 | (0.02) | (0.19) | |
Graham Number |
0.00 | 2.19 | 0.00 | 0.00 | |
Earnings Yield |
(2.61%) | 1.74% | (7.59%) | (34.98%) | |
Free Cash Flow Yield |
(9.65%) | (3.73%) | 5.64% | 6.66% | |
Revenue per Share |
1.19 | 1.78 | 0.29 | 0.34 | |
Operating CF per Share |
0.02 | 0.31 | 0.17 | (0.25) | |
Capex per Share |
(0.02) | (0.04) | (0.02) | (0.01) | |
Free Cash Flow per Share |
0.01 | 0.27 | 0.14 | (0.25) | |
Cash per Share |
0.51 | 0.74 | 0.72 | 0.36 | |
Shareholders Equity per Share |
2.01 | 2.37 | 1.91 | 1.15 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.01 | 2.37 | 1.91 | 1.15 | |
Free Cash Flow |
0.84 | 34.77 | 17.98 | (32.75) | |
Working Capital |
209.43 | 262.06 | 192.48 | 143.34 | |
Capital Expenditures |
(2.23) | (4.65) | (3.15) | (1.10) | |
Net Current Asset Value |
45.05 | 63.59 | (6.94) | (57.88) | |
EV/EBIT |
0.00 | 13.00 | 89.88 | 0.00 | |
Capex to Sales |
0.01 | 0.02 | 0.08 | 0.03 | |
Net Profit Margin |
9.63% | 17.42% | (150.85%) | (227.03%) | |
Price to Operating Income |
0.00 | 14.69 | 118.82 | 0.00 | |
| Other line items | |||||
Average Receivables |
135.03 | 163.66 | 110.11 | 110.66 | |
Average Payables |
32.10 | 30.43 | 26.64 | 29.51 | |
Average Inventory |
33.31 | 27.92 | 28.88 | 31.16 | |
Average Assets |
478.06 | 548.31 | 493.69 | 433.79 | |
Average Common Equity |
266.84 | 281.51 | 243.73 | 190.76 |
Columns are period end dates